Robert S. Wiesenthal - Aug 29, 2025 Form 4 Insider Report for Strata Critical Medical, Inc. (SRTA)

Role: Director
Signature: /s/ Melissa M. Tomkiel, Attorney-in-fact for Robert S. Wiesenthal
Stock symbol: SRTA
Transactions as of: Aug 29, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/3/2025, 08:43 PM
Previous filing: Aug 7, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
WIESENTHAL ROBERT S	Director	C/O STRATA CRITICAL MEDICAL, INC., 31 HUDSON YARDS, 14TH FLOOR, NEW YORK	/s/ Melissa M. Tomkiel, Attorney-in-fact for Robert S. Wiesenthal	2025-09-03	0001211785

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRTA	Class A common stock, $0.0001 par value per share	Award	$0	+40.6K	+0.78%	$0.00	5.28M	Aug 29, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders.
F2	Effective as of September 2, 2025, the terms of 886,886 unvested RSUs granted to the Reporting Person by the Issuer on November 9, 2022 and originally reported by the Reporting Person in Table I of a Form 4 filed on November 14, 2022 and 33,591 unvested RSUs granted to the Reporting Person by the Issuer on December 16, 2021 and originally reported by the Reporting Person in Table I of a Form 4 on December 20, 2021, were amended by the Issuer's board of directors to make them subject to an additional performance-related vesting condition. As a result of such amendment, the shares of the Issuer's common stock underlying such unvested RSUs will no longer be included in the securities beneficially owned by the Reporting Person as reflected in column 5 of Table I. Upon satisfaction of the relevant performance-related vesting condition, the Reporting Person will again report the acquisition of such shares on a Form 4.

Content

Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders.

Effective as of September 2, 2025, the terms of 886,886 unvested RSUs granted to the Reporting Person by the Issuer on November 9, 2022 and originally reported by the Reporting Person in Table I of a Form 4 filed on November 14, 2022 and 33,591 unvested RSUs granted to the Reporting Person by the Issuer on December 16, 2021 and originally reported by the Reporting Person in Table I of a Form 4 on December 20, 2021, were amended by the Issuer's board of directors to make them subject to an additional performance-related vesting condition. As a result of such amendment, the shares of the Issuer's common stock underlying such unvested RSUs will no longer be included in the securities beneficially owned by the Reporting Person as reflected in column 5 of Table I. Upon satisfaction of the relevant performance-related vesting condition, the Reporting Person will again report the acquisition of such shares on a Form 4.